Analyst Update: GoPro, Inc., Ambarella, Inc., and Tekmira Pharmaceuticals Corporation

Analysts adjusted their ratings on GoPro Inc (GPRO), Ambarella Inc (AMBA), and Tekmira Pharmaceuticals Corp (TKMR)

by Griffin Kruse

Published on Mar 30, 2015 at 11:44 AM
Updated on Apr 20, 2015 at 5:32 PM

Analysts are weighing in today on wearable camera maker GoPro Inc (NASDAQ:GPRO), semiconductor firm Ambarella Inc (NASDAQ:AMBA), and biotech issue Tekmira Pharmaceuticals Corp (NASDAQ:TKMR). Here's a quick look at today's brokerage notes on GPRO, AMBA, and TKMR.

  • GPRO is up 1.3% to hit $43.27, after Dougherty & Company raised its opinion on the stock to "buy" from "neutral." The upgrade is somewhat surprising, given the shares of GoPro Inc have fallen about 31.6% year-to-date, and are struggling to conquer resistance at their 40-day moving average. The rest of the brokerage bunch is divided on GPRO, though, as 46% of covering analysts rate the stock a "strong buy," with only 8% doling out "strong sell" recommendations. What's more, the security's average 12-month price target of $63.92 stands at a 47.7% premium to current trading levels, leaving the door wide open for a round of analyst downgrades and/or price-target cuts to create headwinds.

  • Canaccord Genuity lifted its price target on AMBA by $7 to $81 -- in uncharted territory -- while underscoring its "buy" rating, sending the shares 3.9% higher today to reach $73.05. Including today's positive price action, the shares of Ambarella Inc have now advanced an impressive 44% year-to-date. In fact, AMBA tagged a record peak of $73.50 just a week ago. Accordingly, sentiment in the options pits has been bullish, as AMBA's 10-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) call/put volume ratio of 2.75 sits in the 83rd percentile of its annual range.

  • Nomura initiated coverage on TKMR with a "buy" rating and a lofty $32 price target, which represents an 83% premium to the shares' current perch at $17.49, and sits in unexplored terrain. After initially jumping out of the gate, the shares of Tekmira Pharmaceuticals Corp are down about 0.5%, chipping away at a 15.6% year-to-date gain. Calls have been prominent in the options pits, as TKMR's Schaeffer's put/call open interest ratio (SOIR) of 0.23 ranks higher than only 15% of all equivalent readings taken over the past 12 months. Simply stated, near-term speculators have rarely been this call-skewed over the past year. Traders aren't the only ones who are optimistic, either, as all five analysts covering the stock rate it a "buy" or "strong buy."

A Schaeffer's exclusive

6 Sectors for Summer

Access your FREE insider report before it's too late!


  
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


Research Exposes Shortcut to Stock Market Wins
A simple way to stop picking losers, and start cashing in like Wall Street's elite.
Google Postpones Android Reveal, "Now is Not the Time to Celebrate"
"Now is not the time to celebrate," Google said in a message on its website
ZNGA Zooms to 8-Year High on Billion-Dollar Deal
ZNGA is planning to buy Peak for $1.8 billion
Huge New Legal Marijuana Market Has Shortage Crisis
250 million Europeans have access to medical marijuana. There's already a shortage....